InsidersTradesSigma
Follow the Uniphar plc share price and the full directors' dealings record of the company, a publicly traded company based in United Kingdom. Shares are quoted on the UK market, under the supervision of RNS (LSE). Operating in the Healthcare & Pharma sector, Uniphar plc has published 15 insider filings. Market capitalisation: €1.1bn. The latest transaction was filed on 16 May 2026 (Sale). Among the most active insiders: Gerard Rabbette. The full history is free.
15
Insider Decl.
n/a
Thresholds
€38,609
8 ops.
Buy Volume
€474,352
7 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,566 of 29,064 companies
45.7
score / 100
Value55
Quality36
FCF yld4.1%
Earn yld4.6%
EV/EBITDA13.6x
ROE13%
Gross mgn15%
Net mgn1.7%
Debt/EBITDA4.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 May 2026
Declarations15 total
50,000 shares@ €4.2546.4% of flowEuronext DublinISIN IE00BJ5FQX74IE:9569682
50,000 shares@ £4.28353.6% of flowEuronext DublinISIN IE00BJ5FQX74RNS:9569682
50,000 shares@ £0.04250.5% of flowEuronext DublinISIN IE00BJ5FQX74RNS:037cee2c-a2e9-473e-b304-30cf572b2ded
43,355 shares@ £0.03625.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:97b7064a-f44c-4b03-896a-121cf06a6717
100,000 shares@ £0.03812.7% of flowEuronext DublinISIN IE00BJ5FQX74RNS:9cc6356f-71a6-415d-8500-2b986118f46f
200,000 shares@ £0.03326.2% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5650643
38,460 shares@ £0.02214.7% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5451359
490,012 shares@ £0.026673.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5190546-0
326,676 shares@ £0.0266100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5190546-1
107,000 shares@ £0.027516.5% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5143239-0
5,000 shares@ £0.0275100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:5143239-1
50,000 shares@ £0.023100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4929563
87,500 shares@ £0.0230.5% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4924241
105,853 shares@ £0.0235100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4921197-1
84,682 shares@ £0.0225100.0% of flowEuronext DublinISIN IE00BJ5FQX74RNS:4921197-0
15 of 15 declarations
关于 Uniphar plc
Uniphar plc 是一家国际医疗保健服务集团，在伦敦证券交易所（FTSE 100/250/AIM）上市，股票代码为 UPR。公司运营总部位于爱尔兰都柏林，服务范围覆盖欧洲、北美、亚太地区以及中东/北非地区。其客户群包括 200 多家跨国制药、生物技术和医疗技术公司。 Uniphar 拥有悠久的运营历史，集团强调其拥有超过 55 年的经验，这意味着其成立于 1960 年代后期。随着时间的推移，它建立了一个整合的医疗保健平台，涵盖了价值链的多个环节。公司业务结构分为三个核心部门：Uniphar Pharma、Uniphar Medtech 和 Uniphar Supply Chain & Retail。这种组合将高价值服务与分销主导的活动相结合，创造了一个以准入、合规、物流和商业执行为中心的差异化模式。 Uniphar Pharma 整合了准入、医疗和商业能力。这包括扩大准入计划、医疗事务、监管和药物警戒支持、市场准入、上市支持、商业服务和分销。Uniphar Medtech 专注于欧洲医疗器械分销及相关服务，而 Uniphar Supply Chain & Retail 仍然是爱尔兰药品供应链和零售活动的重要平台。该集团不主要销售自有品牌药品；相反，它提供关键的基础设施和服务，帮助制造商将产品推向市场并改善患者的准入。 从竞争角度来看，Uniphar 定位为寻求管理复杂上市、多国准入要求和专业分销需求的制药、医疗技术和生物技术公司的专业合作伙伴。其价值主张建立在端到端服务整合和广泛的地理覆盖之上，公司称其业务遍及 160 多个国家。这使其成为需要监管、商业和供应链支持而非纯粹批发商的创新者的有用合作伙伴。 近期发展强化了这一战略方向。2025 年，Uniphar 将其 On Demand 业务更名为 Uniphar | Global Sourcing，提升了其全球药品采购平台，并通过在美国和欧洲战略性布局的设施扩展了其能力。2026 年，该集团还宣布与 Citius Oncology 签订了 LYMPHIR™ 的独家欧洲分销协议，突显了其在促进复杂疗法准入和支持国际商业化途径方面的作用。 对于投资者而言，Uniphar 最好被视为一家具有防御性特征的医疗保健服务和分销专家，受益于英国伦敦证券交易所（FTSE 100/250/AIM）上市市场中外包制药服务、专业分销和准入解决方案的结构性增长。
